Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Want to see IKT full AI Analyst Report?
Top Page
Inhibikase Therapeutics
(NASDAQ:IKT)
Select Model
Select Model
Rating:53Neutral
Price Target:
$1.50
▼(-18.03% Downside)
Action:Reiterated
Date:05/14/26
The score is primarily held down by very weak financial performance (no TTM revenue, large losses, and ongoing cash burn), partially offset by a strong low-debt balance sheet. Technicals are modestly constructive with neutral momentum, and a positive Phase 3 trial milestone supports the outlook, but valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Low debt / strong balance sheet
A near-zero debt load and roughly $168M of equity provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing pressure, extends runway versus peers, and gives management optionality for trial funding or partnerships without immediate debt reliance.
Negative Factors
No trailing revenue
Zero trailing revenue reflects a pure development-stage business with no product-derived cash flows. That structural lack of commercial income means long-term value creation is binary on clinical/regulatory success and keeps the firm reliant on external funding until commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low debt / strong balance sheet
A near-zero debt load and roughly $168M of equity provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing pressure, extends runway versus peers, and gives management optionality for trial funding or partnerships without immediate debt reliance.
Read all positive factors
Inhibikase Therapeutics (IKT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$233.70M
Dividend YieldN/A
Average Volume (3M)132.72K
Price to Earnings (P/E)―
Beta (1Y)1.58
Revenue GrowthN/A
EPS Growth73.45%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.51
Shares Outstanding132,032,640
10 Day Avg. Volume124,469
30 Day Avg. Volume132,718
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$5.83Price Target Upside218.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$500.00K
Inhibikase Therapeutics Business Overview & Revenue Model
Company Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a sma...
How the Company Makes Money
Inhibikase Therapeutics is a clinical-stage biotechnology company and, based on publicly available information, does not appear to generate material revenue from product sales. Its funding and cash inflows have historically come primarily from fin...
Inhibikase Therapeutics Earnings Call Summary
Earnings Call Date:Aug 14, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments, such as the completion of trial enrollments and financial strengthening, alongside challenges like observed adverse events and increased expenses. The potential for significant advancements, particularly in PAH and Parkinson's disease treatments, is promising, though tempered by some operational hurdles.Positive Updates
Completion of Phase II 201 Trial Enrollment
Inhibikase Therapeutics has completed enrollment for the Phase II 201 Trial for risvodetinib in Parkinson's disease, marking a significant milestone. Top line data from the trial is expected in November.
Negative Updates
Adverse Events in Phase II 201 Trial
In the Phase II 201 Trial, 41 mild and 8 moderate adverse events were observed that may be related to risvodetinib treatment, with 6 participants withdrawing from the trial.
Read all updates
Q2-2024 Updates
Positive
Negative
Completion of Phase II 201 Trial Enrollment
Inhibikase Therapeutics has completed enrollment for the Phase II 201 Trial for risvodetinib in Parkinson's disease, marking a significant milestone. Top line data from the trial is expected in November.
Read all positive updates
Company Guidance
During the Inhibikase Therapeutics Q2 2024 earnings call, executives highlighted several key metrics and developments. The company completed enrollment for the Phase II trial of risvodetinib in Parkinson's disease, expecting to report top-line data in November. They observed 49 adverse events and had six withdrawals from the trial. For their IkT-001Pro, a prodrug formulation aimed at pulmonary arterial hypertension (PAH), they filed an IND on August 9, 2024, with plans for a Phase IIb trial involving around 100 patients. Financially, Inhibikase reported a net loss of $5.0 million for the quarter, with R&D expenses decreasing by $1.5 million to $3.1 million, and a cash position of $7.9 million as of June 30, 2024. The company expects its cash runway to extend into December 2024, bolstered by raising $4 million in May from registered direct offering and concurrent private placement.Inhibikase Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 260.50K | 123.44K | 3.10M |
| Gross Profit | 0.00 | 0.00 | -26.27K | -13.36M | 116.72K | -8.26M |
| EBITDA | -55.75M | -53.29M | -27.49M | -19.91M | -18.05M | 0.00 |
| Net Income | -50.96M | -48.26M | -27.52M | -19.03M | -18.05M | -14.79M |
Balance Sheet | ||||||
| Total Assets | 173.33M | 181.20M | 98.60M | 14.51M | 24.94M | 42.47M |
| Cash, Cash Equivalents and Short-Term Investments | 170.37M | 178.76M | 97.54M | 13.25M | 23.05M | 40.75M |
| Total Debt | 0.00 | 0.00 | 110.52K | 622.00K | 351.29K | 248.91K |
| Total Liabilities | 5.71M | 8.30M | 3.73M | 3.53M | 3.90M | 4.05M |
| Stockholders Equity | 167.62M | 172.90M | 94.87M | 10.98M | 21.04M | 38.42M |
Cash Flow | ||||||
| Free Cash Flow | -36.19M | -27.79M | -19.15M | -18.10M | -17.59M | -14.30M |
| Operating Cash Flow | -35.74M | -27.79M | -19.15M | -18.09M | -17.35M | -14.30M |
| Investing Cash Flow | -99.49M | 2.05M | -37.00M | 11.66M | -16.01M | 0.00 |
| Financing Cash Flow | 111.36M | 108.46M | 103.48M | 8.41M | -204.77K | 41.09M |
Inhibikase Therapeutics Technical Analysis
Neutral
1.83
Price Trends
1.79
Negative
1.79
Negative
1.71
Positive
Market Momentum
-0.04
Positive
47.19
Neutral
68.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IKT, the sentiment is Neutral. The current price of 1.83 is above the 20-day moving average (MA) of 1.82, above the 50-day MA of 1.79, and above the 200-day MA of 1.71, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 47.19 is Neutral, neither overbought nor oversold. The STOCH value of 68.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IKT.
Inhibikase Therapeutics Risk Analysis
Inhibikase Therapeutics disclosed 82 risk factors in its most recent earnings report. Inhibikase Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inhibikase Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $233.70M | -3.38 | -41.31% | ― | ― | 73.45% | |
53 Neutral | $167.91M | 10.64 | 35.58% | ― | 93.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $44.69M | -1.20 | -84.91% | ― | ― | -40.23% | |
| ― | $90.53M | -8.71 | -65.55% | ― | ― | 19.02% | |
45 Neutral | $303.73M | -0.84 | 309.79% | ― | -35.61% | -68.92% | |
43 Neutral | $70.58M | -1.13 | -91.94% | ― | 106.65% | 12.20% |
* Healthcare Sector Average
IKT
Inhibikase Therapeutics
1.75
-0.30
-14.63%
ATOS
Atossa Therapeutics
5.23
-7.77
-59.78%
ANIX
Anixa Biosciences
2.70
-0.19
-6.57%
SPRO
Spero Therapeutics
2.83
0.09
3.28%
SRZN
Surrozen
26.21
18.08
222.39%
TCRX
TScan Therapeutics
1.08
-0.38
-26.03%
Inhibikase Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Inhibikase Begins Pivotal Phase 3 Trial in PAH
Positive
Apr 7, 2026
On April 7, 2026, Inhibikase Therapeutics announced it had enrolled the first patient in its global pivotal Phase 3 IMPROVE-PAH study of IKT-001 for the treatment of Pulmonary Arterial Hypertension. The trial’s launch marks a significant ope...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.